Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06162585 · ClinicalTrials.gov registry record

Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study

A clinical trial of Retinitis Pigmentosa and Eye Diseases, sponsored by Nanoscope Therapeutics.

Active
Registry status
18
Enrollment target
6
Study locations

NCT06162585 is a study of Retinitis Pigmentosa and Eye Diseases that is active but no longer recruiting, run by Nanoscope Therapeutics. The registered enrollment target is 18 participants, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (93% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06162585, a study of Retinitis Pigmentosa and Eye Diseases, is active but no longer recruiting, sponsored by Nanoscope Therapeutics.

ACTIVE NOT RECRUITING
Registry status
18 participants
Enrollment target
6
Study locations

Study Summary

This study will be conducted following Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) guidelines. Eligible subjects will be consented to return for scheduled study visits for this study following their completion in study NTXMCO-002 (RESTORE). They will not receive a second treatment with MCO-010 (or a repeated sham injection) in this study

Conditions Studied

Retinitis Pigmentosa Eye Diseases Retinal Degeneration Eye Diseases, Hereditary Retinal Dystrophies Retinal Diseases Retinitis

Interventions

  • BIOLOGICAL Gene Therapy product-MCO-010

Study Locations (6)

Texas

  • Nanoscope Clinical Site - Houston
  • Nanoscope Clinical Site - McAllen

California

  • Nanoscope Clinical Site - Beverly Hills

Florida

  • Nanoscope Clinical Site - Pensacola

North Dakota

  • Nanoscope Clinical Site - Fargo

Other

  • Nanoscope Clinical Site - Arecibo

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2023-12-08
Est. Completion 2027-09

Sponsor

Nanoscope Therapeutics

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06162585

The ClinicalTrials.gov registry entry for NCT06162585 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (93% lower). The listed sponsor is Nanoscope Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 1 intervention - of which Gene Therapy product-MCO-010 is the first listed.

NCT06162585 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Texas, California, Florida.

Frequently Asked Questions

What is clinical trial NCT06162585 about?

NCT06162585 is a clinical study titled "Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study". This study will be conducted following Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) guidelines. Eligible subjects will be consented to return for scheduled study visits for this study following their completion in study NTXMCO-002 (RESTORE). They will not receive ...

What is the current status of trial NCT06162585?

This trial is currently active not recruiting. The enrollment target is 18 participants. The study started on 2023-12-08. Estimated completion is 2027-09.

What conditions does trial NCT06162585 study?

This clinical trial studies the following conditions: Retinitis Pigmentosa, Eye Diseases, Retinal Degeneration, Eye Diseases, Hereditary, Retinal Dystrophies.

What interventions are being tested in trial NCT06162585?

The interventions under investigation include: Gene Therapy product-MCO-010 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06162585?

This trial is sponsored by Nanoscope Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06162585 being conducted?

This trial has 6 study locations across California, Florida, North Dakota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Retinitis Pigmentosa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Retinitis Pigmentosa

All registered trials for this condition

Eye Diseases

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.